Abstract
To clarify the role of DNA methylation in the silencing of the expression of cyclin-dependent kinase inhibitor p57KIP2 seen in certain tumors, we investigated the methylation status of its 5′ CpG island in various tumor cell lines and primary cancers. Dense methylation of the region around the transcription start site was detected in 1 out of 10 colorectal, 2 out of 8 gastric, and 6 out of 14 hematopoietic tumor cell lines and in 5 out of 35 (14%) gastric, 6 out of 20 (30%) hepatocellular, and 2 out of 18 (11%) pancreatic cancers; 7 out of 25 (28%) acute myeloid leukemia cases also showed methylation of the p57KIP2 gene, which strongly correlated with the CpG island methylator phenotype (P<0.001). Detailed mapping revealed that dense methylation of the region around the transcription start site (−300 to +400), but not of the edges of the CpG island, was closely associated with gene silencing. 5-aza-2′-deoxycytidine, a methyltransferase inhibitor, restored expression of p57KIP2, and chromatin immunoprecipitation using anti-histone H3 and H4 antibodies showed histone to be deacetylated in cell lines where p57KIP2 was methylated at the transcription start site. Regional methylation and histone deacetylation thus appear to be crucially involved in the silencing of p57KIP2 expression in human tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- CDK:
-
cyclin dependent kinase
- RT–PCR:
-
reverse transcriptase PCR
- TSA:
-
trichostatin A
- HDAC:
-
histone deacetylase
- CIMP:
-
CpG island methylator phenotype
References
Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG . 2001 Hum. Mol. Genet. 10: 687–692
Bepler G, Garcia-Blanco MA . 1994 Proc. Natl. Acad. Sci. USA 91: 5513–5517
Bird A . 2002 Genes Dev. 16: 6–21
Bird AP, Wolffe AP . 1999 Cell 99: 451–454
Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB . 1999a Nat. Genet. 21: 103–107
Cameron EE, Baylin SB, Herman JG . 1999b Blood 94: 2445–2451
Chung WY, Yuan L, Feng L, Hensle T, Tycko B . 1996 Hum. Mol. Genet. 5: 1101–1108
Clark SJ, Harrison J, Paul CL, Frommer M . 1994 Nucleic Acids Res. 22: 2990–2997
el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B . 1993 Cell 75: 817–825
Elledge SJ . 1996 Science 274: 1664–1672
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG . 2000 J. Natl. Cancer Inst. 92: 564–569
Fujita N, Shimotake N, Ohki I, Chiba T, Saya H, Shirakawa M, Nakao M . 2000 Mol. Cell. Biol. 20: 5107–5118
Hatada I, Mukai T . 1995 Nat. Genet. 11: 204–206
Hatada I, Ohashi H, Fukushima Y, Kaneko Y, Inoue M, Komoto Y, Okada A, Ohishi S, Nabetani A, Morisaki H, Nakayama M, Niikawa N, Mukai T . 1996 Nat. Genet. 14: 171–173
Herman JG, Jen J, Merlo A, Baylin SB . 1996 Cancer Res. 56: 722–727
Issa JP . 2000 Curr. Top. Microbiol. Immunol. 249: 101–118
Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, Wilson C, Lander E, Jaenisch R . 2001 Nat. Genet. 27: 31–39
Jones PA . 1999 Trends Genet. 15: 34–37
Jones PA, Laird PW . 1999 Nat. Genet. 21: 163–167
Krskova-Honzatkova L, Cermak J, Sajdova J, Stary J, Sedlacek P, Sieglova Z . 2001 Leuk. Res. 25: 45–53
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M . 1997 Nat. Med. 3: 231–234
Matsumoto M, Furihata M, Ohtsuki Y, Sasaguri S, Ogoshi S . 2000 Anticancer Res. 20: 1947–1952
Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ . 1995 Genes Dev. 9: 650–662
Matsuoka S, Thompson JS, Edwards MC, Bartletta JM, Grundy P, Kalikin LM, Harper JW, Elledge SJ, Feinberg AP . 1996 Proc. Natl. Acad. Sci. USA 93: 3026–3030
Mummaneni P, Yates P, Simpson J, Rose J, Turker MS . 1998 Nucleic Acids Res. 26: 5163–5169
Ng HH, Jeppesen P, Bird A . 2000 Mol. Cell. Biol. 20: 1394–1406
Oya M, Schulz WA . 2000 Br. J. Cancer 83: 626–631
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M . 1995 Science 269: 682–685
Salem CE, Markl ID, Bender CM, Gonzales FA, Jones PA, Liang G . 2000 Int. J. Cancer 87: 179–185
Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, Bolondi L, Croce CM, Barbanti-Brodano G, Negrini M . 2000 Proc. Natl. Acad. Sci. USA 97: 5445–5449
Sherr CJ . 2000 Cancer Res. 60: 3689–3695
Sheu JC, Lin YW, Chou HC, Huang GT, Lee HS, Lin YH, Huang SY, Chen CH, Wang JT, Lee PH, Lin JT, Lu FJ, Chen DS . 1999 Br. J. Cancer 80: 468–476
Shin JY, Kim HS, Lee KS, Kim J, Park JB, Won MH, Chae SW, Choi YH, Choi KC, Park YE, Lee JY . 2000a Exp. Mol. Med. 32: 79–83
Shin JY, Kim HS, Park J, Park JB, Lee JY . 2000b Cancer Res. 60: 262–265
Tokino T, Urano T, Furuhata T, Matsushima M, Miyatsu T, Sasaki S, Nakamura Y . 1996 Hum. Genet. 97: 625–631
Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JP . 1999a Proc. Natl. Acad. Sci. USA 96: 8681–8686
Toyota M, Ahuja N, Suzuki H, Itoh F, Ohe-Toyota M, Imai K, Baylin SB, Issa JP . 1999b Cancer Res. 59: 5438–5442
Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP . 1999c Cancer Res. 59: 4535–4541
Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP . 2001 Blood 97: 2823–2829
Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP . 2000 Cancer Res. 60: 4044–4048
Tycko B . 2000 J. Clin. Invest. 105: 401–407
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, Goggins M . 2000 Cancer Res. 60: 1835–1839
Watanabe H, Pan ZQ, Schreiber-Agus N, DePinho RA, Hurwitz J, Xiong Y . 1998 Proc. Natl. Acad. Sci. USA 95: 1392–1397
Winqvist R, Mannermaa A, Alavaikko M, Blanco G, Taskinen PJ, Kiviniemi H, Newsham I, Cavenee W . 1993 Cancer Res. 53: 4486–4488
Wong DJ, Foster SA, Galloway DA, Reid BJ . 1999 Mol. Cell. Biol. 19: 5642–5651
Xiong Z, Laird PW . 1997 Nucleic Acids Res. 25: 2532–2534
Yan Y, Frisen J, Lee MH, Massague J, Barbacid M . 1997 Genes Dev. 11: 973–983
Zhang P, Liegeois NJ, Wong C, Finegold M, Hou H, Thompson JC, Silverman A, Harper JW, DePinho RA, Elledge SJ . 1997 Nature 387: 151–158
Acknowledgements
This study is supported by the Grant-in-Aid for Scientific Research on Priority Areas from the Ministry of Eduction, Culture, Sport, Science, and Technology (M Toyota, F Itoh, T Tokino and K Imai). T Kikuchi is a research fellow from the Japanese Society for the Promotion of Science. H Suzuki is a postdoctoral fellow from the Japanese Society for the Promotion of Science. The authors thank Dr William F Goldman for editing the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kikuchi, T., Toyota, M., Itoh, F. et al. Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors. Oncogene 21, 2741–2749 (2002). https://doi.org/10.1038/sj.onc.1205376
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205376
Keywords
This article is cited by
-
TBX3 promotes proliferation of papillary thyroid carcinoma cells through facilitating PRC2-mediated p57KIP2 repression
Oncogene (2018)
-
RNA-Seq reveals the existence of a CDKN1C-E2F1-TP53 axis that is altered in human T-cell lymphoblastic lymphomas
BMC Cancer (2018)
-
Protein Palmitoylation Regulates Neural Stem Cell Differentiation by Modulation of EID1 Activity
Molecular Neurobiology (2016)
-
Epigenetics and Lymphoma: Can We Use Epigenetics to Prime or Reset Chemoresistant Lymphoma Programs?
Current Oncology Reports (2015)
-
A mechanistic role for the chromatin modulator, NAP1L1, in pancreatic neuroendocrine neoplasm proliferation and metastases
Epigenetics & Chromatin (2014)